Mustang Bio Inc (MBIO) News

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR...

Form 8-K - Current report

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and...

Form 8-K - Current report

Form 8-K - Current report

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq:...

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

   Data showed favorable safety profile, complete response rate and durability in the treatment of patients...

Form 8-K - Current report

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a...